Patents Assigned to Pfizer
  • 3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
    Patent number: 5688804
    Abstract: The present invention relates to the derivatives of the compound of formula (I), which are useful in the treatment of inflammatory and central nervous system disorders, as well as other diorders ##STR1##
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: November 18, 1997
    Assignee: Pfizer Inc.
    Inventor: Terry J. Rosen
  • 5-heteroarylindole derivatives
    Patent number: 5688809
    Abstract: The present invention relates to compounds of the formula ##STR1## The present invention also relates to intermediates for the preparation of compounds of the formula I, pharmaceutical compositions and method of use.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: November 18, 1997
    Assignee: Pfizer Inc.
    Inventor: John E. Macor
  • Spiroazacyclic derivatives as substance P antagonists
    Patent number: 5688806
    Abstract: The present invention relates to novel spirocyclic piperidine derivatives and related compounds and, specifically, to compounds of the formula ##STR1## wherein X, Z, Y, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and m are as defined in the specification, and to intermediates used in the synthesis of such compounds. The novel compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
    Type: Grant
    Filed: October 12, 1995
    Date of Patent: November 18, 1997
    Assignee: Pfizer Inc.
    Inventors: Manoj C. Desai, Lawrence A. Vincent
  • 3-aryl-2-isoxazolines as antiinflammatory agents
    Patent number: 5686434
    Abstract: This invention relates to 3-aryl-2-isoxazoline compounds which are selective inhibitors of phosphodiesterase type IV (PDE.sub.IV). The 3-aryl-2-isoxazolines are useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, dermatitis, shock, atopic dermatitis, rheumatoid arthritis and osteoarthritis. This invention also relates to pharmaceutical compositions useful therefor.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: November 11, 1997
    Assignee: Pfizer Inc.
    Inventor: Edward Fox Kleinman
  • Fused proteins
    Patent number: 5686268
    Abstract: This invention relates to composite somatotropin peptides and fusion protein thereof useful in the potentiating of growth hormone activity. Also disclosed are vector and host cells useful in the recombinant production of such molecules. Vaccines containing composite somatotropin and fusion proteins thereof and methods of using same as disclosed.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: November 11, 1997
    Assignee: Pfizer Inc.
    Inventors: Hector Wasunna Alila, Michael Thomas Clark, Elaine Verne Jones, Timothy Joe Miller, Shawn Patrick O'Brien, Ganesh Madhusudan Sathe
  • hPDE IV-C: a novel human phosphodiesterase IV isozyme
    Patent number: 5686286
    Abstract: This invention relates to a novel nucleic acid sequence encoding a novel human phosphodiesterase IV (hPDE IV) isozyme. It also relates to a polypeptide encoded by such sequence.This invention also relates to an assay method for detecting the presence of such novel isozyme in human cells, and to a method of identifying compounds or other substances that inhibit or modify the activity of such isozyme.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 11, 1997
    Assignee: Pfizer Inc.
    Inventor: Douglas A. Fisher
  • Method for precipitating natural advermectins
    Patent number: 5686274
    Abstract: A process for separating a natural B avermectin from a natural avermectin containing fermentation broth by using an aqueous precipitation. The process comprises extracting natural avermectins from the fermentation broth with a water miscible solvent and adding sufficient water to precipitate the natural B avermectins. Preferably, the water miscible solvent is a C.sub.1 -C.sub.3 alcohol, acetone, or acetonitrile. In addition, an acid, base, salt or surfactant may be added to facilitate the precipitation. This invention provides an isolation technique that substitutes the use of an aqueous precipitation for nonaqueous solvent precipitations. The reduction in use of nonaqueous solvents provides economic, environmental and safety benefits.
    Type: Grant
    Filed: January 16, 1996
    Date of Patent: November 11, 1997
    Assignee: Pfizer Inc.
    Inventor: Abdullah R. Ali
  • Intermediate for azithromycin
    Patent number: 5686587
    Abstract: A compound having formula (III). Also, a process of making azithromycin comprising reducing the compound of formula (III) and N-methylating the reduced product.
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: November 11, 1997
    Assignee: Pfizer Inc.
    Inventor: Bingwei V. Yang
  • Stereoselective preparation of substituted piperidines
    Patent number: 5686615
    Abstract: Novel processes are disclosed for the stereoselective preparation of substituted piperidine derivatives of the formulae ##STR1## wherein R.sup.1 and R.sup.2 are defined as below, useful as substance P receptor antagonists and in treating diseases mediated by an excess of substance P.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: November 11, 1997
    Assignee: Pfizer Inc
    Inventor: Terry J. Rosen
  • Process for producing 5-hydroxy-6-demethyl-6-desoxy-6-methylene-11A-chlorotetracycline
    Patent number: 5686634
    Abstract: In a process for dehydrating 5-hydroxy-11a-chlorotetracycline-6,12-hemiketal to 5-hydroxy-6-demethyl-6-desoxy-6-methylene-11a-chlorotetracycline, utilizing an acid which is not decomposable by water, formic acid serves as a solvent free from chlorinated hydrocarbons.
    Type: Grant
    Filed: July 1, 1994
    Date of Patent: November 11, 1997
    Assignee: Pfizer, Inc.
    Inventors: Wolfgang Kruger, Gisela Kruger
  • Hydrogenated naphthalenes and related LTB.sub.4 antagonists
    Patent number: 5684046
    Abstract: Described herein are Benzopyran and other benzo-fused leukotriene B.sub.4 antagonists have the formula ##STR1## wherein R.sup.1 is a phenyl or substituted phenyl group, and A, n, R.sup.2 and R.sup.3 are as defined herein.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: November 4, 1997
    Assignee: Pfizer Inc
    Inventor: Kevin Koch
  • Cycloalkyl hydroxyureas
    Patent number: 5681858
    Abstract: The present invention provides a novel N-hydroxyurea compound of chemical formula (I) wherein R.sup.1 and R.sup.2 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl; Ar is phenyl or mono-, di- or trisubstituted phenyl; A is a valence bond or a C.sub.1 -C.sub.6 alkylene chain, optionally having one double bond or one triple bond in the chain, and optionally having one or more C.sub.1 -C.sub.4 alkyl groups attached to the chain: X is oxygen or sulfur, n is an integer of 3 to 6; M is hydrogen, pharmaceutically acceptable cation or a metabolically cleavable group: and X and A may be attached at any available position on the ring. These compounds are useful for treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.
    Type: Grant
    Filed: October 3, 1995
    Date of Patent: October 28, 1997
    Assignee: Pfizer Inc.
    Inventors: Rodney William Stevens, Takashi Mano, Yoshiyuki Okumura, Masami Nakane
  • Actinomadura roseorufa for making UK-61,689
    Patent number: 5679563
    Abstract: Actinomadura roseorufa mutants characterized by the ability to produce by fermentation UK-61,689, an acidic polycyclic ether anticoccidial antibiotic previously available only by selective acid hydrolysis of UK-58,852; and Actinomadura roseorufa having the identifying characteristics of ATCC 53,666, ATCC 53,665, ATCC 53,664 and ATCC 53,674.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 21, 1997
    Assignee: Pfizer Inc.
    Inventor: Edward J. Tynan, III
  • Antibacterial 16-membered ring macrolides containing olefins at C-20
    Patent number: 5677287
    Abstract: The present invention relates to C-20 olefin derivatives of 16-membered macrolide antibiotics repromicin, rosaramicin, 5-mycaminosyltylonolide, desmycosin, lactenocin, O-demethyllactenocin, 4'-deoxymycaminosyltylonolide and 23-deoxymycaminosyltylonolide, which are useful against bacterial and mycoplasmic pathogens in animals. Also claimed are a pharmaceutical composition of such derivatives and their use in treating bacterial and mycoplasmic infections in animals.
    Type: Grant
    Filed: September 11, 1995
    Date of Patent: October 14, 1997
    Assignee: Pfizer Inc.
    Inventor: Burton Humphrey Jaynes
  • Antiparasitic agents
    Patent number: 5677332
    Abstract: This invention is directed to novel antiparasitic compounds of formula (I), wherein the broken line represents an optional bond, R.sup.1 and R.sup.4 being absent when this bond is present, R.sup.1, R.sup.3, R.sup.4 are independently H, OH, halo mercapto, oxo, oximino, or an organic radical, R.sup.2 and R.sup.7 are organic radicals, R.sup.6 is H or an organic radical and R.sup.12 is OH, halo, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.9 alkanoyloxy, or oximino optionally O-substituted by a C.sub.1 -C.sub.8 alkyl, alkenyl, alkynyl, aryl, trialkylsilyl, aralkyl or C.sub.1 -C.sub.9 alkanoyl group.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: October 14, 1997
    Assignee: Pfizer Inc.
    Inventor: Bernard Joseph Banks
  • Method of preparing azatetralones
    Patent number: 5677458
    Abstract: Compounds of the formula ##STR1## which are intermediates in the preparation of hydantoin aldose reductase inhibitors and methods of preparing these intermediates.
    Type: Grant
    Filed: October 3, 1996
    Date of Patent: October 14, 1997
    Assignee: Pfizer Inc.
    Inventor: George J. Quallich
  • Benzopyranes as potassium channel openers
    Patent number: 5677324
    Abstract: The present invention relates to compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein the dashed line represents an optional covalent bond; X is O, NH, S or a direct link; R.sup.3 is hydroxy when the dashed line does not represent a covalent bond and R.sup.3 is absent when the dashed line represents a covalent bond; R.sup.4 is (a), when X is O, a group of formula (i), (b), when X is O, NH or S, optionally substituted hydroxyphenyl, (c) an optionally substituted 4- to 7-membered heterocyclic ring, or (d), when X is NH, a group of formula (ii). The compounds are useful for the treatment of disease associated with the altered tone or motility of smooth muscle.
    Type: Grant
    Filed: August 4, 1995
    Date of Patent: October 14, 1997
    Assignee: Pfizer Inc.
    Inventors: Alexander Roderick Mackenzie, Sandra Marina Monaghan
  • Rapamycin producer
    Patent number: 5674732
    Abstract: The present invention provides a novel culture which belongs to Actinoplanes (Actinoplanes sp. FERM BP-3832). This culture is capable of producing rapamycin more than ten times efficiently than the cultures which have been reported (e.g., Streptomyces hygroscopicus ATCC 29253). The present invention provides a process for the production of rapamycin which comprises cultivating Actinoplanes sp. FERM BP-3832 and thereafter isolating rapamycin from the fermentation mixture.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: October 7, 1997
    Assignee: Pfizer Inc.
    Inventors: Hiroyuki Nishida, Tatsuo Sakakibara, Yuji Yamauchi, Taisuke Inagaki, Yasuhiro Kojima, Nakao Kojima
  • Continuous cell line and vaccine against avian coccidia
    Patent number: 5674484
    Abstract: A non-lymphoid continuous cell line adapted for propagation of avian coccidia is provided. This cell line is useful for the production of vaccine antigens for prophylactic treatment of poultry, particularly in a vaccine for coccidia.
    Type: Grant
    Filed: July 11, 1994
    Date of Patent: October 7, 1997
    Assignee: Pfizer Inc.
    Inventors: Timothy J. Miller, Robert A. Clare, Patricia Lufburrow
  • hPDE IV-C: a human phosphodiesterase IV isozyme
    Patent number: 5672509
    Abstract: This invention relates to a novel nucleic acid sequence encoding a novel human phosphodiesterase IV (hPDE IV) isozyme. It also relates to a polypeptide encoded by such sequence.This invention also relates to an assay method for detecting the presence of such novel isozyme in human cells, and to a method of identifying compounds or other substances that inhibit or modify the activity of such isozyme.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: September 30, 1997
    Assignee: Pfizer Inc.
    Inventor: Douglas A. Fisher